Periodontitis, Coronary Disease
Conditions
Brief summary
Cardiovascular diseases (CVD) are still considered the main cause of mortality and morbidity all over the world. In the last years, efforts have been made to define more effective therapeutic and preventive strategies.Periodontal diseases have been considered a probable risk factor for CVD with a great amount of evidence from observational studies. Although there are some interventional studies evaluating the systemic effects of periodontal therapy, there is little information regarding the impact of periodontal treatment on the prevention of cardiovascular events. To the best of our knowledge, there are no randomized controlled trials published to date assessing the effect of periodontal therapy in primary prevention of CVD.
Interventions
BEHAVIORALIntegrated Care Group
The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
OTHERStandard Care Group
The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
Sponsors
Saibliss Healthcare Vision
Macmillan Research Group UK
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Individuals having at least 50% of their dentition with periodontal probing pocket depths N4 mm and * With documented radiographic alveolar bone loss were included
Exclusion criteria
* Known systemic diseases * History and/or presence of other infections * Systemic antibiotic treatment in the preceding 3 months * Treatment with any medication known to affect the serum level of inflammatory markers, lipids, or BP * Pregnant or lactating females * Allergy to tetracyclines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Traditional cardiovascular risk markers (total cholesterol, LDL-C, HDL-C and triglycerides) | Change from baseline to six month |
Secondary
| Measure | Time frame |
|---|---|
| High- and low-density lipoprotein cholesterol | Change from baseline to six month |
| cardiovascular risk scores (Framingham) | Change from baseline to six months |
Other
| Measure | Time frame |
|---|---|
| Blood Pressure and Sugar | Change from baseline to six months |
Countries
India
Outcome results
None listed